Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications.

Welch BT, Packard AT, Atwell TD, Johnson GB, Lowe VJ, Karnes RJ, Mynderse LA, Gunderson TM, Park SS, Stish BJ, Evans JD, Kwon ED, Davis BJ, Nathan MA.

Adv Radiat Oncol. 2018 Sep 5;4(1):79-89. doi: 10.1016/j.adro.2018.08.022. eCollection 2019 Jan-Mar.

2.

Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease.

Parker WP, Davis BJ, Park SS, Olivier KR, Choo R, Nathan MA, Lowe VJ, Welch TJ, Evans JD, Harmsen WS, Zaid HB, Sobol I, Moreira DM, Haloi R, Tollefson MK, Gettman MT, Boorjian SA, Mynderse LA, Karnes RJ, Kwon ED.

Eur Urol. 2017 Mar;71(3):340-348. doi: 10.1016/j.eururo.2016.08.055. Epub 2016 Sep 3.

3.

Role of 18F-Choline PET/CT in guiding biopsy in patients with risen PSA levels and previous negative biopsy for prostate cancer.

Jiménez Londoño GA, García Vicente AM, Amo-Salas M, Fúnez Mayorga F, López Guerrero MA, Talavera Rubio MP, Gutierrez Martin P, González García B, de la Torre Pérez JA, Soriano Castrejón ÁM.

Rev Esp Med Nucl Imagen Mol. 2017 Jul - Aug;36(4):241-246. doi: 10.1016/j.remn.2017.01.014. Epub 2017 Mar 18. English, Spanish.

4.

Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes?

Incerti E, Fodor A, Mapelli P, Fiorino C, Alongi P, Kirienko M, Giovacchini G, Busnardo E, Gianolli L, Di Muzio N, Picchio M.

J Nucl Med. 2015 Dec;56(12):1836-42. doi: 10.2967/jnumed.115.163741. Epub 2015 Sep 24.

5.

Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?

Van den Bergh L, Koole M, Isebaert S, Joniau S, Deroose CM, Oyen R, Lerut E, Budiharto T, Mottaghy F, Bormans G, Van Poppel H, Haustermans K.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1486-92. doi: 10.1016/j.ijrobp.2011.10.046. Epub 2012 Jan 26.

PMID:
22284686
6.

Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.

Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):526-535. doi: 10.1016/j.ijrobp.2016.11.014. Epub 2016 Nov 17.

7.

Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer.

Mattes MD, Moshchinsky AB, Ahsanuddin S, Rizk NP, Foster A, Wu AJ, Ashamalla H, Weber WA, Rimner A.

Clin Lung Cancer. 2015 Nov;16(6):e253-8. doi: 10.1016/j.cllc.2015.06.001. Epub 2015 Jun 15.

PMID:
26163919
8.

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S.

Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):55-63. doi: 10.1007/s00259-010-1604-0. Epub 2010 Sep 17.

PMID:
20848281
9.

Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.

Testa C, Schiavina R, Lodi R, Salizzoni E, Corti B, Farsad M, Kurhanewicz J, Manferrari F, Brunocilla E, Tonon C, Monetti N, Castellucci P, Fanti S, Coe M, Grigioni WF, Martorana G, Canini R, Barbiroli B.

Radiology. 2007 Sep;244(3):797-806. Epub 2007 Jul 24.

PMID:
17652190
10.

Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.

Fodor A, Berardi G, Fiorino C, Picchio M, Busnardo E, Kirienko M, Incerti E, Dell'Oca I, Cozzarini C, Mangili P, Pasetti M, Calandrino R, Gianolli L, Di Muzio NG.

BJU Int. 2017 Mar;119(3):406-413. doi: 10.1111/bju.13510. Epub 2016 May 24.

11.

18F-Fluciclovine parameters on targeted prostate biopsy associated with true positivity in recurrent prostate cancer.

Abiodun-Ojo OA, Akintayo AA, Akin-Akintayo OO, Tade FI, Nieh PT, Master VA, Alemozaffar M, Osunkoya AO, Goodman MM, Fei B, Schuster DM.

J Nucl Med. 2019 Apr 6. pii: jnumed.119.227033. doi: 10.2967/jnumed.119.227033. [Epub ahead of print]

PMID:
30954940
12.

Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness.

Chen J, Zhao Y, Li X, Sun P, Wang M, Wang R, Jin X.

Radiol Oncol. 2012 Sep;46(3):179-88. doi: 10.2478/v10019-012-0034-y. Epub 2012 Jun 19.

13.

Imaging prostate cancer with 11C-choline PET/CT.

Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, Möller P, Glatting G, Perner S.

J Nucl Med. 2006 Aug;47(8):1249-54.

14.

Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.

Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.

BJU Int. 2015 Jun;115(6):874-83. doi: 10.1111/bju.12953. Epub 2015 Jan 21.

15.

18F-FECH PET/CT to Assess Clinically Significant Disease in Prostate Cancer: Correlation With Maximum and Total Cancer Core Length Obtained via MRI-Guided Template Mapping Biopsies.

Haroon A, Ahmed HU, Cathcart P, Almuhaideb A, Kayani I, Dickson J, Kirkham A, Freeman A, Emberton M, Bomanji J.

AJR Am J Roentgenol. 2016 Dec;207(6):1297-1306. Epub 2016 Sep 9.

PMID:
27611962
16.

Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker.

Leisser A, Pruscha K, Ubl P, Wadsak W, Mayerhöfer M, Mitterhauser M, Hacker M, Kramer G, Shariat S, Karanikas G, Hartenbach M, Haug AR.

Prostate. 2015 Nov;75(15):1760-7. doi: 10.1002/pros.23061. Epub 2015 Aug 18.

PMID:
26282590
17.

Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.

Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F.

Eur Urol Focus. 2018 Mar 30. pii: S2405-4569(18)30086-5. doi: 10.1016/j.euf.2018.03.008. [Epub ahead of print]

PMID:
29609897
18.

Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy.

Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, Da Pozzo L, Bocciardi A, Rigatti P, Fazio F.

Eur Urol. 2007 Aug;52(2):423-9. Epub 2007 Mar 20.

PMID:
17397992
19.

18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.

Piert M, Montgomery J, Kunju LP, Siddiqui J, Rogers V, Rajendiran T, Johnson TD, Shao X, Davenport MS.

J Nucl Med. 2016 Jul;57(7):1065-70. doi: 10.2967/jnumed.115.170878. Epub 2016 Mar 16.

20.

Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET.

Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN.

J Nucl Med. 2006 Feb;47(2):262-9.

Supplemental Content

Support Center